KR20220008316A - Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법 - Google Patents

Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법 Download PDF

Info

Publication number
KR20220008316A
KR20220008316A KR1020217040782A KR20217040782A KR20220008316A KR 20220008316 A KR20220008316 A KR 20220008316A KR 1020217040782 A KR1020217040782 A KR 1020217040782A KR 20217040782 A KR20217040782 A KR 20217040782A KR 20220008316 A KR20220008316 A KR 20220008316A
Authority
KR
South Korea
Prior art keywords
cancer
patient
tumor
treatment
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217040782A
Other languages
English (en)
Korean (ko)
Inventor
미셸 모로우
피오나 게르마셰브스키
다니엘 글리돈
킨-메이 렁
크리스티안 그래디나루
크리스토퍼 셰퍼드
조세핀-비트 홀즈
루이스 케이타리르
Original Assignee
에프-스타 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906807.1A external-priority patent/GB201906807D0/en
Priority claimed from GB201914040A external-priority patent/GB201914040D0/en
Priority claimed from GBGB2000318.2A external-priority patent/GB202000318D0/en
Application filed by 에프-스타 테라퓨틱스 리미티드 filed Critical 에프-스타 테라퓨틱스 리미티드
Publication of KR20220008316A publication Critical patent/KR20220008316A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217040782A 2019-05-14 2020-05-14 Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법 Ceased KR20220008316A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1906807.1 2019-05-14
GBGB1906807.1A GB201906807D0 (en) 2019-05-14 2019-05-14 Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
GB1914040.9 2019-09-30
GB201914040A GB201914040D0 (en) 2019-09-30 2019-09-30 Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GBGB2000318.2A GB202000318D0 (en) 2020-01-09 2020-01-09 Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
GB2000318.2 2020-01-09
PCT/EP2020/063529 WO2020229626A1 (en) 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Publications (1)

Publication Number Publication Date
KR20220008316A true KR20220008316A (ko) 2022-01-20

Family

ID=70775359

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217040782A Ceased KR20220008316A (ko) 2019-05-14 2020-05-14 Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법

Country Status (12)

Country Link
US (1) US20220275092A1 (https=)
EP (1) EP3969477A1 (https=)
JP (1) JP2022533578A (https=)
KR (1) KR20220008316A (https=)
CN (1) CN114206939A (https=)
AU (1) AU2020275209A1 (https=)
BR (1) BR112021022831A2 (https=)
CA (1) CA3139003A1 (https=)
IL (1) IL287979A (https=)
MX (1) MX2021013943A (https=)
SG (1) SG11202112136RA (https=)
WO (1) WO2020229626A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
PT3820569T (pt) 2018-07-12 2025-01-14 Invox Pharma Ltd Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
JP7850884B2 (ja) * 2021-03-31 2026-04-24 メルス・ベー・フェー 新規多重特異性抗体
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210602T1 (hr) * 2016-06-20 2021-05-14 F-Star Delta Limited Vezujuće molekule koje vežu pd-l1 i lag-3
ES2965352T3 (es) * 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物

Also Published As

Publication number Publication date
JP2022533578A (ja) 2022-07-25
WO2020229626A1 (en) 2020-11-19
AU2020275209A1 (en) 2021-12-23
MX2021013943A (es) 2022-01-04
US20220275092A1 (en) 2022-09-01
IL287979A (en) 2022-01-01
CN114206939A (zh) 2022-03-18
EP3969477A1 (en) 2022-03-23
SG11202112136RA (en) 2021-11-29
BR112021022831A2 (pt) 2022-01-18
CA3139003A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
KR20220008316A (ko) Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법
US11767361B2 (en) Method of treating lung cancer
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
KR102661249B1 (ko) 종양 치료용 항-ｂ7-ｈ1 항체
Mau-Sørensen et al. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3
JP6805428B2 (ja) Ｃｅａｃａｍ１に対するヒト化抗体
CA3061874A1 (en) Il-1beta binding antibodies for use in treating cancer
US11572405B2 (en) Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer
US12565528B2 (en) LAG-3 antagonist therapy for lung cancer
US20220249621A1 (en) TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS
KR20210084560A (ko) Pd-1/pd-l1 신호전달 억제제에 반응하지 않는 암을 치료하기 위한 방법 및 약제
SG11202110694RA (en) Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
RU2818587C2 (ru) Режимы дозирования при введении биспецифичного антитела против lag -3/pd-l1
US20240156908A1 (en) USE OF sEphB4-HSA FUSION PROTEIN AS A FIRST-LINE THERAPY IN CANCER TREATMENT
HK40118859A (zh) 用於治疗肿瘤的抗-cd73、抗-pd-l1抗体和化疗
WO2023192478A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
HK40063551A (en) Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor
HK1172839A (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601